Promising leukemia combo trial pulled before it even started
NCT ID NCT07585734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial aimed to test a new drug called CM313, a CD38-targeting antibody, combined with a chemotherapy regimen inspired by pediatric treatments for adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). The goal was to see if the combination could improve remission rates and reduce the chance of relapse. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM313 (a CD38 monoclonal antibody) combined with a pediatric-inspired chemotherapy regimen (vincristine, daunorubicin, cyclophosphamide, L-asparaginase, prednisone)
- What this could lead to
- If successful, this approach could improve remission rates and reduce relapse in adults with T-ALL, a hard-to-treat leukemia.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data exist. It is very early-stage (phase I/II) and the combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.